Currently, there is no established therapy to treat patients with this cardiomyopathy. Initially, individuals are treated for myocardial infarction until this diagnosis has been disproven [3]. Following a diagnosis of Takotsubo cardiomyopathy, treatment is primarily focused on monitoring and supportive care. Guidelines published by the American Heart Association and the American College of Cardiology in 2014 suggest that patients should be treated with typical medications, including ACE inhibitors, beta-blockers, aspirin, and diuretics as tolerated by the patient’s hemodynamic status [15]. The gene discussed is ACE; the disease is cardiomyopathy.